Pgiam/iStock via Getty Images
Sage Therapeutics (NASDAQ:SAGE) traded lower on Tuesday as the company drew another downgrade on Wall Street—this time from TD Cowen—following its failure in a mid-stage trial for its neuro candidate SAGE-324 developed with Biogen (BIIB).
TD Cowen lowered its rating on SAGE to Hold from Buy following a similar downgrade by J.P. Morgan immediately after the setback, which prompted Biogen (BIIB) and Sage (SAGE) to discontinue studies for the candidate for a condition known as essential tremor last week.
“We also await clarity on the next value-creating data catalysts from SAGE’s pipeline programs,” wrote TD Cowen’s Ritu Baral as she lowered her price target to $10 from $16 per share.
Citing Sage’s (SAGE) Parkinson’s disease candidate SAGE-718, the analyst argued that she had “high hopes” for the drug given its mechanism of action. However, the “data generated to date across 3 indications have been modest to disappointing,” Baral added.
The analyst also wrote that the ongoing market rollout of the company’s newly launched depression therapy, Zurzuvae, is unlikely to generate near-term upside despite its long-term prospects. Baral is awaiting more details on the launch to become more constructive on the stock.







